IP Library Granted Patent US 9,421,298
Granted Patent B2
US 9,421,298 · App. 13/984,186 · Granted Aug 23, 2016

Tissue adhesive based on nitrogen-modified aspartates

Inventors: Heike Heckroth (Odenthal, DE); Christoph Eggert (Köln, DE)
Assignee: Adhesys Medical GmbH
A61L24/046A61L24/0015C08G18/10C08G18/3821C08G18/4252C08G18/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,421,298
App. No.
13/984,186
Granted
Aug 23, 2016
Kind
B2
Abstract

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular; and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention.

Claims (32)

1. A method for sealing, bonding, gluing or covering of a cell tissue comprising preparing a polyurea system comprising

as component A) isocyanate-functional prepolymers obtained by reacting aliphatic isocyanates A1) with

polyols A2),

as component B) amino-functional aspartic acid esters of the general formula (I)

in which

X is an organic radical containing a secondary amino function,

R 1 and R 2 are identical or different organic radicals which have no zerewitinoff-active hydrogen and

n is an integer of at least 2,

applying the polyurea system to the cell tissue

and sealing, bonding, gluing or covering the cell tissue thereby stopping the escape of blood or tissue fluids or sealing leakages in the cell tissue, wherein the polyurea system when cured has no cytotoxicity in accordance with ISO 10993.

2. The method as claimed in claim 1 , wherein X is a radical of the formula (II)

in which

R 3 and R 4 in each case independently of one another, are an organic radical which has no zerewitinoff-active hydrogen.

3. The method as claimed in claim 2 , wherein R 3 and R 4 in each case independently of one another or simultaneously are a linear or branched saturated organic radical optionally also substituted in the chain with heteroatoms.

4. The method as claimed in claim 1 , wherein the radicals R 1 and R 2 in each case independently of one another are linear or branched C1 to C10 organic radicals.

5. The method as claimed in claim 2 , wherein R 3 and R 4 in each case independently of one another or simultaneously are a linear or branched, saturated, aliphatic C2 to C6, and the radicals R 1 and R 2 in each case independently of one another are linear or branched C2 to C4 aliphatic hydrocarbon radicals.

6. The method as claimed in claim 1 , wherein the polyols A2) contain polyesterpolyols and/or polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.

7. The method as claimed in claim 1 , wherein the polyols A2) contain polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.

8. The method as claimed in claim 1 , wherein the polyols A2) have a number-average molecular weight of from 4000 to 8500 g/mol.

9. The method as claimed in claim 1 , wherein it comprises, as component C), organic fillers which have a viscosity at 23° C., measured in accordance with DIN 53019, in the range from 10 to 20 000 meas.

10. The method as claimed in claim 9 , wherein the organic fillers are hydroxy-functional compounds.

11. The method as claimed in claim 10 , wherein the hydroxy-functional compounds are polyetherpolyols.

12. The method as claimed in claim 10 , wherein the hydroxy-functional compounds have an average OH functionality of 1.5 to 3.

13. The method as claimed in claim 10 , wherein the hydroxy-functional compounds have an average OH functionality of 2.

14. The method as claimed in claim 1 , wherein it comprises, as component D) water and/or a tertiary amine, where the tertiary amine is selected from the group consisting of triethanolamine, tetrakis(2-hydroxyethyl)ethylenediamine, N,N-dimethyl-2-(4-methylpiperazin-1-yl)ethanamine, 2-{[2-(dimethylamino)ethyl](methyl)amino}ethanol and 3,3′,3″-(1,3,5-triazinane-1,3,5-triyl)tris(N,N-dimethylpropan-1-amine).

15. The method as claimed in claim 14 , wherein the system comprises 0.2 to 2.0% by weight of water and/or 0.1 to 1.0% by weight of the tertiary amine.

16. The method as claimed in claim 1 , wherein it comprises, as component E) pharmacologically active compounds.

17. The method as claimed in claim 1 , wherein it comprises, as component E) analgesics with or without antiinflammatory effect, antiphlogistics, antimicrobially effective substances or antimycotics.

18. The method as claimed in claim 1 , wherein said polyols A2) have a number-average molecular weight of ≧400 g/mol and an average OH functionality of 2 to 6.

19. The method according to claim 1 , wherein the polyurea system is applied with a dosing system, wherein the dosing system comprises two chambers for the polyurea system wherein, in the one chamber, the component A) is present and, in the other chamber, the components B) and optionally the components C), D) and E) of the polyurea system are present.

20. The method as claimed in claim 1 , wherein component A1) is hexamethylene diisocyanate and component B) is selected from the group consisting of triethyl 4-oxo-3-oxa-7,11,16-triazaoctadecane-6,17,18-tricarboxylate, triethyl 4-oxo-3-oxa-7,14,21-triazatricosane-6,22,23-tricarboxylate, and Triethyl 4-oxo-3-oxa-7,11,15-triazaheptadecane-6,16,17-tricarboxylate.

21. The method as claimed in claim 1 , wherein the polyurea system comprises, as component C), organic fillers which have a viscosity at 23° C., measured in accordance with DIN 53019, in the range from 10 to 20 000 mPas and, as component D) water and/or a tertiary amine, where the tertiary amine is selected from the group consisting of triethanolamine, tetrakis(2-hydroxyethyl)ethylenediamine, N,N-dimethyl-2-(4-methylpiperazin-1-yl)ethanamine, 2-{[2-(dimethylamino)ethyl](methyl)amino}ethanol and 3,3′,3″-(1,3,5-triazinane-1,3,5-triyl)tris(N,N-dimethylpropan-1-amine).

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPL. NO. 13/369,744 PREVIOUSLY RECORDED AT REEL: 038810 FRAME: 0860. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Jul 21, 2016
From: MEDICAL ADHESIVE REVOLUTION GMBH
To: ADHESYS MEDICAL GMBH
Reel/Frame 039427/0230 →
CHANGE OF NAME Recorded May 25, 2016
From: MEDICAL ADHESIVE REVOLUTION GMBH
To: ADHESYS MEDICAL GMBH
Reel/Frame 038810/0860 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 033489 FRAME: 0635. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 30, 2014
From: BAYER MATERIALSCIENCE AG
To: MEDICAL ADHESIVE REVOLUTION GMBH
Reel/Frame 033907/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2014
From: BAYER MATERIALSCIENCE AG
To: MEDICAL ADHESIVE REVOLUTION GMBH
Reel/Frame 033489/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2013
From: HEIKE, HECKROTH; CHRISTOPH, EGGERT
To: BAYER MATERIALSCIENCE AG
Reel/Frame 031032/0792 →
Priority Claims (1)
EP 11153810 · Feb 9, 2011 · regional
Continuity (1)
Related Publication 20130325062A1 · Dec 5, 2013